Chromocell Corporation
http://www.chromocell.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chromocell Corporation
Rapport Navigates Rough IPO Market With Well-Received Offering
Rapport Therapeutics launched an initial public offering in the middle of a proposed price range, and the CNS-focused company closed slightly above its IPO price on its first day of trading.
Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements
Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.
Execs On The Move, June 2017
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Appointments: IFPMA, Merck, Chromocell, Kymab, GW Pharmaceuticals, Fortuna Fix and Motif
This week's roundup includes high level appointments by Merck KGaA, Chromocell Corporation, Kymab and GW Pharmaceuticals, in addition to board appointments by Fortuna Fix and Motif Bio.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice